FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032785602> ?p ?o ?g. }

• W3032785602 endingPage "6513" @default.
• W3032785602 startingPage "6513" @default.
• W3032785602 abstract "6513 Background: Treatment options for aggressive TC are limited. Pre-clinical data suggests efficacy of CTLA-4 plus PD-1 blockade in aggressive RAIR TC. Methods: This investigator initiated phase II study tested N (3mg/kg every 2 weeks) plus I (1mg/kg every 6 weeks) until disease progression or completion of 24 mo of treatment in RAIR differentiated TC including poorly differentiated TC (PDTC) with exploratory cohorts in anaplastic (ATC) and medullary TC (MTC). Radiographic response rate by RECIST v1.1 (CR+PR) was primary endpoint. At least 6 pts with disease response among n=32 DTC provided 84% power to distinguish between a 10% and a 25% RR (one-sided 9% binomial test). Results: Accrual is complete with n=32 patients with DTC, 10 with ATC and 7 with MTC enrolled between October 2017 and May 2019. Thirty-two DTC included: n=17 papillary, n=7 Hurthle, n=4 follicular TC, n=4 PDTC. Among n=49, median (range) age was 65 (30-88), 51% (25/49) were female. To date, in DTC, 3/32 achieved a PR (n=2 Hurthle and n=1 PDTC), 9.4% RR (.95CI:2%-25%). One near complete response has been observed. Among pts w ATC, 3/ 10 profound PR by RECIST occurred (30% RR, .95CI: 7%-65%). Among them, two remain without clear evidence of disease at 26 and 13 mo after treatment start. No PR's were observed in MTC. Most frequent grade 3-4 TRAEs were as expected and included increased lipase (n=8), increased serum amylase (n=4). There was an unexpected number of treatment related adrenal insufficiency (AI) (n=4) which was associated with long PFS (range 10.1—16.4+mo). Conclusions: N+I appears to have considerable activity in ATC. In unselected RAIR DTC, activity was low but responses were seen in PDTC and Hurthle cell TC. Exceptional responses with prolonged remissions were observed. Clinical trial information: NCT03246958 ." @default.
• W3032785602 created "2020-06-05" @default.
• W3032785602 creator A5004313073 @default.
• W3032785602 creator A5011400267 @default.
• W3032785602 creator A5019249879 @default.
• W3032785602 creator A5024024612 @default.
• W3032785602 creator A5035425249 @default.
• W3032785602 creator A5036875036 @default.
• W3032785602 creator A5047594780 @default.
• W3032785602 creator A5048265450 @default.
• W3032785602 creator A5052296730 @default.
• W3032785602 creator A5056593987 @default.
• W3032785602 creator A5060353514 @default.
• W3032785602 creator A5064055509 @default.
• W3032785602 creator A5066002385 @default.
• W3032785602 creator A5072981073 @default.
• W3032785602 creator A5073653003 @default.
• W3032785602 creator A5074870461 @default.
• W3032785602 creator A5077566206 @default.
• W3032785602 creator A5080875822 @default.
• W3032785602 creator A5083795563 @default.
• W3032785602 creator A5089114785 @default.
• W3032785602 date "2020-05-20" @default.
• W3032785602 modified "2023-10-02" @default.
• W3032785602 title "A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)." @default.
• W3032785602 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.6513" @default.
• W3032785602 hasPublicationYear "2020" @default.
• W3032785602 type Work @default.
• W3032785602 sameAs 3032785602 @default.
• W3032785602 citedByCount "27" @default.
• W3032785602 countsByYear W30327856022020 @default.
• W3032785602 countsByYear W30327856022021 @default.
• W3032785602 countsByYear W30327856022022 @default.
• W3032785602 countsByYear W30327856022023 @default.
• W3032785602 crossrefType "journal-article" @default.
• W3032785602 hasAuthorship W3032785602A5004313073 @default.
• W3032785602 hasAuthorship W3032785602A5011400267 @default.
• W3032785602 hasAuthorship W3032785602A5019249879 @default.
• W3032785602 hasAuthorship W3032785602A5024024612 @default.
• W3032785602 hasAuthorship W3032785602A5035425249 @default.
• W3032785602 hasAuthorship W3032785602A5036875036 @default.
• W3032785602 hasAuthorship W3032785602A5047594780 @default.
• W3032785602 hasAuthorship W3032785602A5048265450 @default.
• W3032785602 hasAuthorship W3032785602A5052296730 @default.
• W3032785602 hasAuthorship W3032785602A5056593987 @default.
• W3032785602 hasAuthorship W3032785602A5060353514 @default.
• W3032785602 hasAuthorship W3032785602A5064055509 @default.
• W3032785602 hasAuthorship W3032785602A5066002385 @default.
• W3032785602 hasAuthorship W3032785602A5072981073 @default.
• W3032785602 hasAuthorship W3032785602A5073653003 @default.
• W3032785602 hasAuthorship W3032785602A5074870461 @default.
• W3032785602 hasAuthorship W3032785602A5077566206 @default.
• W3032785602 hasAuthorship W3032785602A5080875822 @default.
• W3032785602 hasAuthorship W3032785602A5083795563 @default.
• W3032785602 hasAuthorship W3032785602A5089114785 @default.
• W3032785602 hasConcept C121332964 @default.
• W3032785602 hasConcept C121608353 @default.
• W3032785602 hasConcept C126322002 @default.
• W3032785602 hasConcept C142424586 @default.
• W3032785602 hasConcept C143998085 @default.
• W3032785602 hasConcept C203092338 @default.
• W3032785602 hasConcept C2776264508 @default.
• W3032785602 hasConcept C2779761222 @default.
• W3032785602 hasConcept C2780120053 @default.
• W3032785602 hasConcept C2780256643 @default.
• W3032785602 hasConcept C2781461381 @default.
• W3032785602 hasConcept C2989005 @default.
• W3032785602 hasConcept C31760486 @default.
• W3032785602 hasConcept C535046627 @default.
• W3032785602 hasConcept C71924100 @default.
• W3032785602 hasConcept C87355193 @default.
• W3032785602 hasConcept C90924648 @default.
• W3032785602 hasConceptScore W3032785602C121332964 @default.
• W3032785602 hasConceptScore W3032785602C121608353 @default.
• W3032785602 hasConceptScore W3032785602C126322002 @default.
• W3032785602 hasConceptScore W3032785602C142424586 @default.
• W3032785602 hasConceptScore W3032785602C143998085 @default.
• W3032785602 hasConceptScore W3032785602C203092338 @default.
• W3032785602 hasConceptScore W3032785602C2776264508 @default.
• W3032785602 hasConceptScore W3032785602C2779761222 @default.
• W3032785602 hasConceptScore W3032785602C2780120053 @default.
• W3032785602 hasConceptScore W3032785602C2780256643 @default.
• W3032785602 hasConceptScore W3032785602C2781461381 @default.
• W3032785602 hasConceptScore W3032785602C2989005 @default.
• W3032785602 hasConceptScore W3032785602C31760486 @default.
• W3032785602 hasConceptScore W3032785602C535046627 @default.
• W3032785602 hasConceptScore W3032785602C71924100 @default.
• W3032785602 hasConceptScore W3032785602C87355193 @default.
• W3032785602 hasConceptScore W3032785602C90924648 @default.
• W3032785602 hasIssue "15_suppl" @default.
• W3032785602 hasLocation W30327856021 @default.
• W3032785602 hasOpenAccess W3032785602 @default.
• W3032785602 hasPrimaryLocation W30327856021 @default.
• W3032785602 hasRelatedWork W2094109552 @default.
• W3032785602 hasRelatedWork W2142421136 @default.
• W3032785602 hasRelatedWork W2183602213 @default.
• W3032785602 hasRelatedWork W2520539248 @default.
• W3032785602 hasRelatedWork W2531120386 @default.

• next